Quironsalud Madrid
| Turchia | Austria | Spagna | |
| Terapia biologica | da $5,500 | da $20,000 | da $15,000 |
| Radioterapia per il cancro colorettale | da $7,000 | da $12,000 | da $10,000 |
| Immunoterapia con Keytruda (Pembrolizumab) | da $3,300 | da $15,000 | da $15,000 |
| Chemioterapia per carcinoma mammario | da $1,200 | da $15,000 | da $3,500 |
| Chemioterapia | da $2,430 | da $2,500 | da $2,500 |
Il medico è un ematologo pediatrico con specializzazione nel trapianto di midollo osseo. Con una vasta esperienza in ematologia pediatrica, il medico ha contribuito in modo significativo ai progressi nel trattamento dei disturbi del sangue nei bambini. Il medico è noto per l'implementazione di tecniche di trapianto innovative che migliorano i risultati dei pazienti e ha pubblicato numerosi articoli di ricerca su riviste mediche di primo piano.<\/p>
Dr. Francesc Cobo Valien is a leading oncohematologist at the Teknon Oncology Institute in Barcelona. He specializes in treating complex blood cancers, including leukemia and lymphoma. Dr. Cobo Valien earned his medical degree and doctorate from the University of Barcelona. He serves patients at Centro Médico Teknon, a JCI-accredited facility.
Il medico è specializzato in linfomi e leucemia linfatica cronica, guidando innovazioni nell'analisi e nel trattamento delle malattie ematologiche. Rinomato a livello globale per la sua esperienza nella Leucemia Linfatica Cronica (CLL), il medico conduce ricerche cliniche e di base significative, concentrandosi sulla patogenesi molecolare e nuovi approcci terapeutici.<\/p>
Attualmente coinvolto in oltre 80 studi dalla fase 1 alla fase 3, il medico contribuisce allo sviluppo di nuovi farmaci e trattamenti. Come Capo dell'Ematologia presso l'IOB Institute of Oncology e Capo del Dipartimento di Ematologia presso il Vall d’Hebron University Hospital, il medico ha pubblicato oltre 100 articoli su riviste prestigiose.<\/p>
Il medico è uno specialista esperto in ematologia oncologica pediatrica e un neurochirurgo pediatrico di spicco in Spagna. Con oltre 30 anni di esperienza pratica, il medico guida l'Unità di Ematologia e Oncologia Pediatrica presso HM Hospitales, concentrandosi su gravi malattie ematologiche e cancerose nei bambini e negli adolescenti.<\/p>
Il medico è specializzato nella diagnosi e nel trattamento dei disturbi ematologici e cancerosi, in particolare nei sistemi eritrocitario, mieloide e linfoide. Il medico serve come consulente per l'OMS e l'UNESCO ed è coinvolto in attività di insegnamento e ricerca.<\/p>
Le credenziali educative includono lauree presso l'Universidad Complutense de Madrid, l'Università di Barcellona e l'Università del Maryland.<\/p>
Spanish clinics treat Hodgkin lymphoma using personalized protocols including ABVD chemotherapy, targeted immunotherapy, and radiation. Accredited centers like Centro Medico Teknon and Clinica Universidad de Navarra integrate bone marrow transplantation for relapsed cases. Pediatric care is centralized at SJD Barcelona Children Hospital using molecular medicine.
Bookimed Expert Insight: Spain ranks fourth globally in our network for oncology requests, reflecting high trust in its hematology infrastructure. Data showing Clinica Universidad de Navarra was first in Spain to receive JCI accreditation highlights a long-standing culture of safety. For complex cases, choosing centers with dedicated oncohematology units like HM Sanchinarro ensures access to integrated multidisciplinary reviews.
Patient Consensus: Patients emphasize that waiting for pathology results is the most stressful phase before starting treatment. Many recommend discussing fertility preservation and requesting PET-adapted scans early to monitor how well the chemotherapy is working.
Surgery is not a standard curative treatment for Hodgkin lymphoma. It is a systemic lymphatic cancer managed primarily with chemotherapy and radiation. High-volume Spanish centers like Clinica Universidad de Navarra utilize surgical intervention strictly for excisional biopsy or managing rare localized relapses.
Bookimed Expert Insight: Spanish hematology centers like SJD Barcelona Children's Hospital emphasize that 90% of pediatric cases bypass surgery for advanced molecular monitoring. With 450,000 patients treated annually, these institutions focus on bone marrow analysis and systemic drug therapies that provide higher long-term survival rates than localized surgical excision can offer for lymphoma.
Patient Consensus: Patients note it's vital to confirm if a procedure is for diagnosis or therapy. They warn never to assume removing one visible node means the cancer is gone.
Children and young adults in Spain receive specialized Hodgkin's lymphoma care through age-tailored medical protocols. Pediatric facilities like SJD Barcelona Children's Hospital treat patients up to 18 years old. Clinical staff prioritize long-term health. These protocols focus on reducing toxicity while maintaining high survival rates.
Bookimed Expert Insight: Data shows a clear distinction between adult and pediatric volume across major Spanish centers. SJD Barcelona Children's Hospital serves 450,000 patients annually with 800 doctors focused solely on pediatrics. This high volume allows for nuanced sub-specialization. In contrast, Clinica Universidad de Navarra treats both adults and children. Families should choose high-volume pediatric units to ensure protocols specifically address growth and development risks.
Patient Consensus: Patients note that teenagers often receive care in pediatric units rather than adult departments. They emphasize the importance of starting fertility preservation discussions immediately before chemotherapy begins.
Chemotherapy for Hodgkin lymphoma in Spain is primarily an outpatient procedure. Patients receive infusions at a day hospital or clinic and return home the same day. Hospitalization is only necessary for intensive multi-day regimens, high-risk first cycles, or managing severe side effects like fever.
Bookimed Expert Insight: Spanish oncology centers like Centro Médico Teknon often prioritize patient comfort by bundling diagnostic markers and proteinograms into quick, one-day outpatient packages. While high-profile clinics in Barcelona and Madrid serve over 400,000 patients annually, they maintain an outpatient-first model. This focus on day-hospital care allows clinics to handle massive patient volumes without sacrificing the personalized monitoring found in smaller units.
Patient Consensus: Patients note that the day of infusion is often easier than the following week. They emphasize having a clear plan for where to go if they develop a fever or severe weakness at home.
Spain offers high-tier Hodgkin's lymphoma care through JCI-accredited centers in Madrid and Barcelona. Spanish oncology institutions report an 85% five-year survival rate for adults. Specialist clinics achieve remission rates up to 95%. These centers provide rapid access to immunotherapy and advanced bone marrow transplantation.
Bookimed Expert Insight: Quality signals for lymphoma care in Spain often correlate with large network affiliations. Hospital HM Nou Delfos and Hospital Universitario HM Sanchinarro are part of the massive HM Hospitals network. These clinics serve over 400,000 patients annually and share specialized oncological research. Choosing a network center ensures access to cross-disciplinary expertise and modern imaging technology like the EOS system.
Patient Consensus: Patients value the multidisciplinary teams in Madrid and Barcelona which combine hematology, imaging, and transplant specialists under one roof. Many appreciate the warmer climate and supportive urban infrastructure which makes long-term recovery more comfortable.
Spanish oncology centers provide advanced therapies for refractory Hodgkin lymphoma. Patients access programmed cell death protein 1 inhibitors and antibody-drug conjugates like brentuximab vedotin. Specialized hospitals in Barcelona and Madrid also offer bone marrow transplantation. These interventions target resistant cancer cells when standard chemotherapy fails.
Bookimed Expert Insight: Spanish centers like Centro Médico Teknon and SJD Barcelona prioritize high-volume experience to manage refractory cases. Prof. Dr. Francesc Bosch has led over 80 clinical trials, offering patients access to protocols not yet available in smaller hospitals. Choosing a JCI-accredited facility in Spain ensures these complex biological therapies are administered under strict international safety standards.
Patient Consensus: Patients emphasize that moving to a major university hospital in Spain is vital for accessing newer drugs like brentuximab. They note that while neuropathy is a concern, these therapies often work when standard regimens have stopped helping.